Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
Source: SeekingAlpha
2025-04-15 06:41:18 ET
...
Read the full article on Seeking Alpha
For further details see:
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
Syros Pharmaceuticals Inc.
NASDAQ: SYRS
SYRS Trading
2.3% G/L:
$0.1172 Last:
14,991,631 Volume:
$0.1145 Open:
SYRS Latest News
February 28, 2025 04:05:00 pm
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
SYRS Stock Data
$21,466
23,542,797
0.01%
7
4194894%
Biotechnology & Life Sciences
Healthcare
US
Cambridge
